article thumbnail

Zebrafish for Disease Modeling and Drug Screening in Pediatric Cancers

biobide

This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes. This treatment was developed by performing a chemical screening on zebrafish.

Disease 59
article thumbnail

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy

Alta Sciences

Not really, although I contemplated medical school for a while. But then I dated a medical student in my first year of university and soon realized I did not think I could handle an entire class of people like him for four to eight years (no offense to MDs everywhere!).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evotec CSO Cord Dohrmann Appointed to German Council of Science and Humanities

The Pharma Data

He subsequently was accepted at Harvard Medical School in Boston, USA, where he received his Ph.D. Furthermore, Evotec developed innovative partnership models with academia, biotech and pharma companies to accelerate the translation of academic discoveries into promising co-owned product opportunities.

Science 52
article thumbnail

Diabetes Smarts – Helping Men & Women To Prevent & Fight Diabetes Symptoms

The Pharma Data

First, most are on the payroll of the big pharma companies earning lucrative commissions for pushing their drugs…. By offering you another natural option, they are going against everything they have been taught during and since medical school and much of what the medical industry stands for….

Doctors 52
article thumbnail

Combo ‘Polypill’ May Cut Heart Attack, Stroke Risk Up to 40%

The Pharma Data

Yang pointed out that “the fact that it’s generic is a double-edged sword, because no big pharma company is willing to invest a lot of money in developing and marketing a polypill. It may require either health insurance companies or governments or charitable organizations to develop polypills.”